)
)
Bavarian Nordic Investor Relations Material
Latest events
Q2 2024
Bavarian Nordic
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Bavarian Nordic
Access all reports
Segment Data
Access more data
Revenue by
Products and services
MVA-BN smallpox vaccine
Rabipur/RabAvert
Encepur
Other product sale
Other
Expenses by
Financials
Bavarian Nordic is a clinical-stage biopharmaceutical company that develops and commercializes life-saving vaccines in the areas of cancer and infectious diseases. Its fast-growing portfolio today includes Aeras, an influenza vaccine that has been approved in the United States, Europe, and Canada, and the company is advancing a pipeline of novel, next generation vaccines designed to complement its portfolio. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.
Key slides for Bavarian Nordic
Q1 2024
Bavarian Nordic
CMD 2024
Bavarian Nordic
Latest articles
)
Intel: Semiconductors & Strategic Inflection Points
Founded in 1968, Intel has been a key player in the American semiconductor industry, with its processors powering computers worldwide.
15 Oct 2024
)
Our Favorite Spin-off Stories Since 2000
Spin-off motives vary widely across different companies, but the underlying objective remains the same: enhancing long-term shareholder value.
17 Oct 2024
)
Walmart: Walton, Retailing, and Everyday Low Prices
Walmart was founded in 1962 by Sam Walton, and has grown to become the largest retailer in the world, employing more than 2.1 million people worldwide.
17 Oct 2024
Ticker symbol
BAVA
Country
🇩🇰 Denmark